Barbara Domayne-Hayman

Barbara Domayne-Hayman- Entrepreneur in Residence and lead for KQ Labs at the Crick

KQ Labs team

Barbara has worked on the commercial side of life sciences for thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech.

Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in-residence, where amongst other things, she helps to run an accelerator called KQ Labs, which is focused on start-ups making use of data/AI applied to health. She is also Chief Business officer of Autifony, where she is responsible for strategic partnering, fundraising and commercial aspects of drug development for CNS disorders.  In December 2017 Autifony signed a major collaboration with Boehringer Ingelheim. She also currently chairs the LifeArc Seed Fund investment committee, and sits on the Cambridge Enterprise Seed Fund Investment Committee. Barbara was also Chair of Puridify, a UCL spin-out with a breakthrough biotherapeutics purification technology, which was acquired by GE in November 2017.  

Previously, Barbara was CEO of Stabilitech, and she was Commercial Director at Arrow Therapeutics until the company was acquired by AstraZeneca. Barbara was also Senior Business Development Manager at Celltech.

Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School.